×

Joint Ministries Initiative to Develop Guidelines for Puberty Blocking Drugs in Minors with Gender Dysphoria

Schillaci and Roccella Collaborating on New guidelines for Triptorelin Dysphoria

Joint Ministries Initiative to Develop Guidelines for Puberty Blocking Drugs in Minors with Gender Dysphoria

After conducting extensive investigative work, the Ministry of Health and the Ministry of Family have initiated a joint discussion on the use of triptorelin, a puberty blocking drug, for gender dysphoria in minors. This discussion is being led by Ministers Orazio Schillaci and Eugenia Roccella. The goal is to develop new guidelines based on a review of scientific literature and experiences from other countries that have reevaluated their positions after widespread use of these drugs.

The two ministries have released a joint statement announcing this initiative and summarizing the work done so far on gender dysphoria and the use of blockers. The statement mentions that this effort follows a hearing with scientific societies involved in the issue of gender dysphoria in adolescents and a request made to the National Bioethics Committee to reevaluate the use of triptorelin in cases of dysphoria in minors. Additionally, the ministries are conducting a survey among regions regarding clinical monitoring, expenditures, and prescriptions of triptorelin for cases of dysphoria, and have requested a report from AIFA on the therapeutic indications for the drug.

This collaborative effort represents a proactive approach to addressing the complex issue of gender dysphoria in minors, with a focus on evidence-based guidelines and best practices. Stay tuned for updates as the table of technicians and experts continues its work to develop new specific guidelines for this important issue.

You May Have Missed